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SUMMARY Psoriasis is a chronic, systemic inflammatory disease associated with sev-
eral cardiometabolic comorbidities, such as obesity, insulin resistance, dyslipidemia, 
and hypertension, and with clinically significant increased risk of cardiovascular disease 
and cardiovascular mortality. These comorbidities are components of the metabolic 
syndrome. Multiple epidemiologic studies have revealed a high prevalence of meta-
bolic syndrome in patients with psoriasis compared with other skin diseases. Genetic 
susceptibility and overlapping inflammatory pathways may be potential biologic links 
underlying this association. Understanding the interrelationship between these condi-
tions is important for the management of psoriasis and its associated comorbidities. 
This review will focus on the range of these comorbidities, with emphasis on the meta-
bolic syndrome, aiming to encourage physicians to screen patients with psoriasis for 
cardiometabolic disorders and risk factors.
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INTRodUCTIoN
Psoriasis is a common chronic inflammatory skin 
disease that affects 1% to 3% of the general popula-
tion (1). It affects both sexes and all ages equally, with 
incidence peaks in early adult life (20s) and later adult 
life (50s and 60s) (2,3). It is clinically characterized by 
sharply demarcated erythematous plaques covered 
by silvery-white scales predominantly at the elbows, 
knees, scalp, umbilicus, and lumbar area, and histo-
logically by epidermal hyperplasia, dilatation, and 
proliferation of dermal blood vessels and accumula-
tion of inflammatory cells, particularly neutrophils 
and T lymphocytes in the dermis (4). Both genetic 
and environmental factors are involved in its patho-
physiology (5-7).
Although rarely life threatening, psoriasis has a 
negative impact on quality of life, similar to that of 
patients living with diabetes, cancer, or heart disease 
(8), a fact reported by most patients. More than skin 
deep, psoriasis is nowadays considered a systemic 
inflammatory disorder (9) associated with numerous 
medical comorbidities and with clinically significant 
increased risk of cardiovascular disease (CVD) and 
cardiovascular mortality (10-13). The increased in-
flammatory load of psoriasis may play an important 
role in the accelerated atherosclerosis observed in 
these patients (14), as inflammatory processes play a 
key role in atherogenesis, including infiltration of in-
flammatory cells into the arterial intima and secretion 
of cytokines (15). Due to this higher incidence of car-
diovascular disease, life expectancy for patients with 
severe psoriasis is reduced by up to 5 years (16).
MeTABoLIC SYNdRoMe
“Syndrome X” was the term proposed by Reaven 
in 1988 for the combination of hyperinsulinemia, hy-
pertension, glucose intolerance, high triglycemia, and 
low high-density lipoprotein (HDL) cholesterol (17). A 
year later, Kaplan used the term “the deadly quartet”, 
adding another component, upper body obesity, to 
the trio of hypertension, glucose intolerance, and 
high triglycemia (18). In 1991, DeFronzo proposed 
the term “insulin resistance syndrome”, characterized 
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by the combination of obesity, hypertension, lipid 
abnormalities, non-insulin-dependent diabetes mel-
litus (DM), and atherosclerotic cardiovascular disease 
(19). Lamarche called the combination of high apoli-
poprotein B levels, high small, dense low-density lipo-
protein (LDL), and hyperinsulinemia “the atherogenic 
metabolic triad” (20). Finally, in 1999, the World Health 
Organization used “metabolic syndrome” to designate 
a cluster of risk factors that includes central obesity, 
atherogenic dyslipidemia, hypertension, and glucose 
intolerance (21). 
Metabolic syndrome affects approximately 15% 
to 25% of the general population (22,23) and is con-
sidered a strong predictor of cardiovascular disease, 
diabetes, and stroke (24,25). The combination of all its 
components confers a significant greater risk of de-
velopment of cardiovascular disease than the attrib-
utable risk of each individual component risk factor. 
There are several diagnostic criteria for meta-
bolic syndrome. The National Cholesterol Education 
Program Adult Treatment Panel III (NCEP ATP III) is 
widely used in the USA and Europe, and defines the 
metabolic syndrome as the presence of 3 or more of 
the following components: abdominal obesity (waist 
circumference ≥102cm in men, ≥88cm in women), in-
creased insulin resistance/high fasting glucose (≥100 
mg/dL or treatment), decreased HDL (<40 mg/dL in 
men, <50 mg/dL in women, or treatment), hypertri-
glyceridemia (≥150 mg/dL or treatment), and hyper-
tension (systolic blood pressure ≥130 mmHg or dia-
stolic blood pressure ≥85 mmHg, or treatment) (26). 
Thought to arise from insulin resistance and ab-
normal adipose tissue function (27), it is characterized 
Table 1. Study population characteristics and outcomes: Psoriasis and metabolic syndrome
Study Study setting Study design
Total no. of patients Measure of association(95% CI)
Control Psoriasis
Sommer et al. (33) 
(2006)
Germany; inpatient
(hospital charts) Cross-sectional 1044
581 
(hospitalized
psoriasis pts)
OR 4.22 (2.06-8.65)
Gisondi et al. 
(32)(2007)
Italy; outpatient
(outpatient clinics) Cross-sectional 334 338 OR 1.65 (1.16-2.35)
Cohen et al (34) 
(2007) Israel Cross-sectional 48681 16851 OR 1.3 (1.1–1.4)
Chen et al. (50) 
(2008)
Taiwan; outpatient
(dermatology clinics) Case-control 81 77 OR 0.84 (0.31-2.26)
Chen et al. (51) 
(2009)
Taiwan; outpatient
(dermatology clinics) Case-control 37 40 OR 2.40 (0.67-8.58)
Al-Mutairi et al. 
(30) (2010)
Kuwait; outpatient
(medical records) Case-control 1835 1835
Mild psoriasis: OR 2.62 (2.09-3.28)
Severe psoriasis: OR 4.93 (3.21-7.60)
Augustin et al. 
(52) (2010)
Germany; outpatient
(health insurance 
database)
Cross-sectional 1310090 33981 OR 2.86 (2.21-3.71)
Bongiorno et al. 
(53) (2010)
Italy; outpatient
(dermatology 
department)
Cross-sectional 348 400 OR 3.4 (2.23-5.24)
Nisa and Qazi (54) 
(2010)
India; outpatient
(dermatology 
department)
Case-control 150 150 OR 6.09 (NR)
Takahashi et al. 
(55) (2010)
Japan; outpatient
(dermatology clinic) Case-control 154 151 OR 1.74 (0.99-3.05)
Love et al. (44) 
(2011)
United States; 
outpatient (NHANES) Cross-sectional 2385 71
OR 2.16 (1.16-4.03)
AOR 1.96 (1.02-3.77)
Mebazaa et al. 
(31) (2011)
Tunisia; outpatient
(dermatology clinic) Case-control 216 164
OR 1.39 (0.88-2.18)
AOR 1.73 (1.06-2.82)
Langan et al. (45) 
(2012)
United Kingdom; 
outpatient
(THIN database)
Case-control 40650 4065
OR 1.50 (1.40-1.61)
Overall AOR 1.41 (1.31-1.51)
Mild psoriasis: AOR 1.22 (1.11-1.35)
NHANES, National Health and Nutrition Examination Survey; pts, patients; THIN, The Health Improvement 
Network; AOR, Adjusted odds ratio; OR, odds ratio; CI, confidence interval; NR, not reported.
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by a low-grade pro inflammatory state with several 
pro-inflammatory cytokines (e.g., TNF-α, IL-6), adipo-
kines (e.g. leptin, resitin) and non-specific measures 
of inflammation (e.g., C reactive protein) levels, which 
are elevated when compared to levels in the absence 
of metabolic syndrome (28).
PSoRIASIS ANd MeTABoLIC SYNdRoMe
Several recent population-based studies have 
suggested a relationship between psoriasis and met-
abolic syndrome, with patients suffering from psoria-
sis having an increased risk of metabolic syndrome 
(29-36). 
Genetic susceptibility and overlapping inflam-
matory pathways may be potential biological links 
underlying this association (37,38). The existence of 
pleiotropic genetic loci (e.g., PSORS2-4, CDKAL 1, and 
ApoE4) has been implicated in the shared genetic sus-
ceptibility to both psoriasis and metabolic syndrome 
(39,40). On the other hand, the chronic and systemic 
Th-1- and Th-17-mediated inflammation of psoriasis 
characterized by increased levels of pro-inflamma-
tory cytokines, such as tumor necrosis factor-α and 
interleukin-6, not only promotes epidermal hyperpla-
sia in psoriasis, but also antagonizes insulin signaling, 
alters adipokine expression, and mediates insulin re-
sistance and obesity (37,38). Furthermore, the chroni-
cally high levels of free fatty acids associated with 
both metabolic syndrome and psoriasis may lead to 
adipocyte dysfunction and inhibit insulin secretion, 
and also induce apoptosis of pancreatic b-islet cells 
through an endoplasmic stress response leading to 
the development of type 2 diabetes (41). Finally, the 
altered adipokine expression and function found in 
psoriasis may also explain the association between 
psoriasis and metabolic syndrome. For instance, the 
leptin antiapoptotic properties on the β-islet cells 
seem to be reduced in obese psoriasis patients. Thus, 
the combined dysfunction of leptin, adiponectin, re-
sistin, and visfatin described in psoriasis may account 
for the development of metabolic syndrome and oth-
er conditions associated with atherosclerosis seen in 
patients with psoriasis (42,43).
Several studies have reported the association be-
tween psoriasis and metabolic syndrome (Table 1).
Sommer et al. (33) showed, in a cross-sectional 
study with 581 hospitalized patients with psoriasis 
and 1044 controls, that the patients had a significant-
ly increased risk of metabolic syndrome than controls 
(OR=4.22; 95% Confidence interval (CI)=2.06-8.65). 
In a hospital-based case-control study that included 
338 patients with psoriasis and 334 patients with 
other skin diseases, Gisondi et al. found that the pre-
dominance of metabolic syndrome was significantly 
higher in the psoriasis group than in the control 
group (30.1% vs 20.6%; OR=1.65; 95% CI=1.16-2.35). 
Concerning the individual components of the meta-
bolic syndrome, they found that the predominance of 
hypertrygliceridemia and abdominal obesity was also 
increased in psoriasis patients compared to controls, 
while no difference was observed between cases and 
controls with respect to low levels of HDL, DM, and 
hypertension (32). A cross-sectional study conducted 
in Israel using the database of the Clalit Health Servic-
es, with 16851 patients with psoriasis and 48681 con-
trols, demonstrated a significant association of pso-
riasis with metabolic syndrome (OR=1.3; 95% CI=1.1-
1.4) (34). In the USA, Love et al. reported significant 
increased risk of metabolic syndrome in patients with 
psoriasis compared with controls even after adjust-
ment for age, sex, race/ethnicity, smoking, and C-re-
active protein levels (OR=1.96; 95% CI=1.01-3.77) (44). 
In a population-base prevalence study in the United 
Kingdom using the Health Improvement Network da-
tabase, with 4065 psoriasis patients and 40650 control 
subjects, metabolic syndrome was identified in 34% 
Table 2. AHA recommendations for risk factor screening 
Measurement Recommendation Target
Pulse Evaluated at least every 2 years
Blood pressure Evaluated at least every 2 years <120/80 mmHg
Body mass index Evaluated at least every 2 years <25 kg/m2
Waist circumference Evaluated at least every 2 years <88 cm for women; <102 cm for men
Fasting blood glucose
Evaluated at least every 5 years or every 2 
years if risk factors are present
<100 mg/dL
Fasting serum lipoprotein 
or total and HDL 
cholesterol
Evaluated at least every 5 years or every 2 
years if risk factors are present (a positive 
family history, presence of diabetes or 
smoking habits)
Total cholesterol < 200 mg/dL
HDL ≥ 50 mg/dL
LDL: Optimal < 100 mg/dL; near optimal/Above 
optimal 100 to 129 mg/dL; Borderline high 130 
to 159 mg/dL; High 160 to 189 mg/dL; Very high 
190 mg/dL and above
Sales and Torres Acta Dermatovenerol Croat
Psoriasis and metabolic syndrome  2014;22(3):169-174
172 ACTA DERMATOVENEROLOGICA CROATICA
of participants with psoriasis compared to 26% of 
controls, (OR=1.50; 95% CI=1.40-1.61), with this asso-
ciation persisting after adjusting for age, gender, and 
follow up (adjusted OR=1.41; 95% CI=1.31-1.51). Fur-
thermore, psoriasis severity affected the degree of as-
sociation, with metabolic syndrome seen in 32% with 
mild psoriasis (adjusted OR=1.22; 95% CI=1.11-1.35), 
36% with moderate psoriasis (adjusted OR=1.56; 95% 
CI=1.38-1.76), and 40% of those with severe psoria-
sis (adjusted OR=1.98; 95% CI=1.62-2.43). In addition, 
obesity, hypertriglyceridemia, and hyperglycemia 
demonstrated dose-response association with pso-
riasis severity independently of other components 
(45). A recent meta-analysis, synthesizing data from 
12 studies for a total of 41853 patients with psoriasis 
from more than 1.4 million total participants, showed 
that the odds of metabolic syndrome were increased 
more than two-fold among patients with psoriasis 
when compared with matched controls or a cross-
sectional comparator group (OR=2.26; 95% CI=1.70-
3.01) (46).
 Despite increasing evidence of this association 
and the importance of identifying and modifying the 
psoriasis associated cardio-metabolic comorbidities, 
it appears that clinical practical implementation is ac-
cording to our opinion still modest. 
A high predominance of undiagnosed and un-
dertreated cardiovascular risk factors was found in a 
large cohort of patients (n=2899) with moderate to 
severe psoriasis enrolled in a phase III clinical trial of 
ustekinumab. And even if these cardiovascular risk 
factors had been diagnosed, there was a high rate 
of failure to achieve treatment goals per published 
guidelines (47). Furthermore, Parsi et al. assessed car-
diovascular risk factor screening practices in patients 
with psoriasis among primary care physicians and 
cardiologists and their awareness of worse cardiovas-
cular outcomes in these patients; and less than half of 
the physicians screened these patients for cardiovas-
cular risk factors per guidelines and less than half of 
all physicians were aware that patients with psoriasis 
had more serious cardiovascular adverse events com-
pared with the general population (48).
In 2008, the National Psoriasis Foundation re-
leased screening guidelines and recommendations 
for treatment of cardiovascular risk factors in patients 
with psoriasis, based on the 2002 American Heart 
Association update (50). These recommendations in-
clude risk factor screening as early as age 20: hyper-
tension (blood pressure ≥140/≥90 mmHg), diabetes 
(fasting plasma glucose ≥126 mg/dL), hyperlipidemia 
(fasting LDL-cholesterol ≥160 mg/dL or triglycerides 
≥200 mg/dL), obesity (BMI≥30), and metabolic syn-
drome. By age 40, medical evaluation is recommend-
ed every two years, consisting of the following mea-
surements: pulse, blood pressure with target <120/80 
mmHg, body mass index with target <25 kg/m2, and 
waist circumference with target <88 cm for women 
and <102 cm for men. Fasting blood glucose should 
be evaluated at least every 5 years or every 2 years if 
other risk factors are present; target value should be 
<100 mg/dL. Fasting serum lipoprotein or total and 
HDL cholesterol should be evaluated at least every 5 
years or every 2 years if a positive family history car-
diovascular disease, diabetes, or smoking habits are 
present. Total cholesterol should be <200mg/dL, HDL 
≥50mg/dL, and LDL <130 mg/dL (49) (Table 2).
Additionally, all psoriasis patients, particularly 
those with metabolic syndrome, should be encour-
aged in lifestyle modifications including moderate al-
cohol intake, healthy eating habits, quitting smoking, 
and exercising 3 times a week for 30 minutes. 
CoNCLUSIoN
There is increasing evidence that psoriasis is asso-
ciated with metabolic syndrome. 
Psoriasis should not be regarded as a simple skin 
condition but rather as a systemic inflammatory dis-
ease associated with several cardiometabolic comor-
bidities and increased risk of cardiovascular disease. 
Physicians should be aware of this association and look 
beyond the skin symptoms. It is important that patients 
with psoriasis are subjected to appropriate screening 
as part of routine medical care, that metabolic syn-
drome is correctly managed, and that all patients with 
psoriasis are encouraged to correct their modifiable 
cardiovascular risk factors, adopting healthier life-style 
behaviors such as regular physical activity.
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